UB376
TargetsGLP-1R
IndicationsObesity; Diabetes mellitus
ClinicalCN - I、US - IND
TherapeuticsMetabolic & Endocrinology
ModalitiesSmall Molecule
Exclusive Summary
- • Potent G-protein biased agonist of hGLP1R.
- • Robust effects in glucose tolerance tests in mice and Superior in vivo efficacy in DIO mice & obese monkey models vs. Orforglipron.
- • Micellar formulation developed in-house to improve the drug bioavailability.
- • No requirement for spray-dried dispersions (used for orforglipron) may provide advantage in manufacturing costs.
- • Robust safety package, including 13-week studies in monkeys and mouse EFD studies.
- • Solid patents layout.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →